Trade Y-mAbs Therapeutics, Inc. - YMAB CFD

Trading Conditions

• Spread: 0.13
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 15.23
• Open: 14.28
• 1-Year Change: 143.27%
• Day's Range: 14.28 - 15.33

Y-mAbs Therapeutics, Inc. Company profile

About Y-mAbs Therapeutics Inc

Y-mAbs Therapeutics, Inc. is a commercial-stage clinical biopharmaceutical company. The Company is focused on the development and commercialization of novel, antibody based therapeutic products for the treatment of cancer. Its product pipeline includes DANYELZA (naxitamab-gqgk), which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor, or GM-CSF,for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. It also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The Company is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Y-mAbs Therapeutics Inc revenues increased 68% to $34.9M. Net loss decreased 54% to $55.3M. Revenues reflect License revenue increase of 59% to $32.9M. Lower net loss reflects Foreign Exchange Gain/LossNon-Business increase from $576K (expense) to $1.9M (income), Licensing royalties decrease of 90% to $210K (expense), Research and development - Balancing val decrease of 2% to $83.5M (expense).